| Literature DB >> 27260156 |
Andrew J Aguirre1, Robin M Meyers2, Barbara A Weir3, Francisca Vazquez3, Cheng-Zhong Zhang3, Uri Ben-David2, April Cook3, Gavin Ha3, William F Harrington2, Mihir B Doshi3, Maria Kost-Alimova2, Stanley Gill3, Han Xu2, Levi D Ali2, Guozhi Jiang2, Sasha Pantel2, Yenarae Lee2, Amy Goodale2, Andrew D Cherniack2, Coyin Oh2, Gregory Kryukov3, Glenn S Cowley2, Levi A Garraway4, Kimberly Stegmaier5, Charles W Roberts6, Todd R Golub7, Matthew Meyerson8, David E Root2, Aviad Tsherniak9, William C Hahn10.
Abstract
UNLABELLED: The CRISPR/Cas9 system enables genome editing and somatic cell genetic screens in mammalian cells. We performed genome-scale loss-of-function screens in 33 cancer cell lines to identify genes essential for proliferation/survival and found a strong correlation between increased gene copy number and decreased cell viability after genome editing. Within regions of copy-number gain, CRISPR/Cas9 targeting of both expressed and unexpressed genes, as well as intergenic loci, led to significantly decreased cell proliferation through induction of a G2 cell-cycle arrest. By examining single-guide RNAs that map to multiple genomic sites, we found that this cell response to CRISPR/Cas9 editing correlated strongly with the number of target loci. These observations indicate that genome targeting by CRISPR/Cas9 elicits a gene-independent antiproliferative cell response. This effect has important practical implications for the interpretation of CRISPR/Cas9 screening data and confounds the use of this technology for the identification of essential genes in amplified regions. SIGNIFICANCE: We found that the number of CRISPR/Cas9-induced DNA breaks dictates a gene-independent antiproliferative response in cells. These observations have practical implications for using CRISPR/Cas9 to interrogate cancer gene function and illustrate that cancer cells are highly sensitive to site-specific DNA damage, which may provide a path to novel therapeutic strategies. Cancer Discov; 6(8); 914-29. ©2016 AACR.See related commentary by Sheel and Xue, p. 824See related article by Munoz et al., p. 900This article is highlighted in the In This Issue feature, p. 803. 2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27260156 PMCID: PMC4972686 DOI: 10.1158/2159-8290.CD-16-0154
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397